ABL Bio announced that its partner, I-MAB, presented a poster featuring Phase 1 pharmacokinetic (PK) modeling data on ABL111/Givastomig at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), held in Houston, Texas, from November 6th  to 10th.

ABL111/Givastomig is a bispecific antibody targeting Claudin 18.2 and 4-1BB. ABL Bio and I-MAB are evaluating its potential as a first-line treatment through an ongoing Phase 1b clinical trial targeting patients with metastatic gastric cancer.

The poster, revealed on November 9 in the poster hall of the George R. Brown Convention Center, included analyses of clinical and preclinical data aimed at identifying the optimal dosage for ABL111/ Givastomig.

According to the poster, a dose-response relationship for ABL111/Givastomig was established, with an optimal dosage range of 8–12 mg/kg (administered biweekly) for gastric cancer patients. Based on these findings, ABL Bio and I-MAB are conducting a Phase 1b trial that combines ABL111/Givastomig with chemotherapy and nivolumab in Claudin 18.2-positive metastatic gastric cancer patients who have not received prior treatment.

CEO of ABL Bio, stated, "ABL111/Givastomig, a bispecific antibody utilizing Grab body-T technology, not only binds precisely to cancer cells but also maintains strong anti-tumor activity while minimizing liver and systemic immune toxicities commonly observed in 4-1BB monoclonal antibodies. Topline data from the dose-escalation part of the Phase 1b trial for the triple combination therapy are expected in the second half of next year."